Philip Morris International’s nicotine pouches ZYN brand to feature on Scuderia Ferrari HP Formula 1 motorsport liveries
Philip Morris International (PMI) Inc has expanded its partnership with Scuderia Ferrari HP by launching a bold new chapter in their long-standing relationship to feature PMI’s nicotine pouches ZYN brand on Scuderia Ferrari HP Formula 1 and Ferrari Challenge Trofeo Pirelli motorsport liveries at select races throughout the 2026 season and beyond.
In a statement, PMI indicates that this bold new chapter reinforces a spirit of relentless innovation and unforgettable experiences that has defined the partnership for more than five decades — making it one of the strongest in sports history.
These races as the single-marque motorsport championship that were created in 1993 and to mark this moment, ZYN branding will first feature on the Scuderia Ferrari HP car livery during the Abu Dhabi Grand Prix 2025 scheduled for December 7.
Stefano Volpetti, President Smoke-Free Products & Chief Consumer Officer-PMI, is quoted in the statement saying: “PMI shares with Scuderia Ferrari HP the pursuit to innovate and challenge the status quo for millions of adults that share this passion.
“By engaging in this space, we demonstrate our commitment on this journey. By further enhancing our partnership with Scuderia Ferrari HP, we hope to accelerate the replacement of cigarettes, and we want our adult consumers of nicotine products, like ZYN, to embrace and enjoy every moment of this thrilling ride.”
ZYN nicotine pouches — the number one nicotine pouch brand globally — is the only authorised by the U.S. Food and Drug Administration as appropriate to protect public health as it is not risk-free and contain nicotine, which is addictive.
They are intended only for legal-aged adult consumers of nicotine products and are not alternatives to quitting tobacco and nicotine altogether.
On the part of Ferrari, Chief Racing Revenue Officer, Lorenzo Giorgetti, said: “Ferrari has always valued partnerships built on innovation, responsibility and a vision-oriented toward continuous improvement, with a forward-looking mindset.
“Our renewed collaboration with PMI is a concrete expression of this approach and continues a relationship that has lasted for over 50 years, grounded in scientific progress and long-term thinking.
“As PMI advances the development of smoke-free alternatives, we are proud to evolve together, uniting our shared values of excellence, discipline and innovation to drive progress both on and off the track,” he said.
Responsible Marketing
PMI’s maintains that marketing and sales policies and practices reflect its commitment to market all its products responsibly.
“This means increasing adult consumers’ awareness and understanding of our smoke-free product portfolio while guarding against access to our products by unintended audiences.
“Formula 1 — with its overwhelmingly adult audience — is a global platform where we engage adult consumers worldwide with a message of choice and innovative alternatives to cigarettes.
Global Smoke-Free Champion
PMI is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.
The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products.
“Our smoke-free products are available for sale in over 100 markets, and as of June 30, 2025, PMI estimates they were used by over 41 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption.
“The smoke-free business accounted for 41% of PMI’s first-nine months 2025 total net revenues. Since 2008, PMI has invested over US$14 billion to develop, scientifically substantiate and commercialise innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes.
“This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies.”
Following a robust science-based review, PMI amplifies that the U.S. Food and Drug Administration has authorised the marketing of Swedish Match’s General snus and ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables — “the first-ever such authorizations in their respective categories”.
“Versions of IQOS devices and consumables and general snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA — and with a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences.”
Follow and Subscribe Nyasa TV :